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Introduction
Atrial fibrillation (AF) is a cardiac arrhythmia that affects 
thousands of hospitalized Americans, with an increasing prevalence 
in the United States[1],[2]. Atrial fibrillation is frequently observed as a 
complication of acute myocardial infarction (AMI), affecting 5-13% 
of all patients suffering an AMI[3]-[7]. New-onset and prevalent AF 
is not only associated with higher rates of  in-hospital complications 
such as heart failure, stroke, and death[7]-[10], but also a higher likelihood 
of re-hospitalization among hospital survivors of an AMI[7].
The CHADS2 and CHA2DS2VASc scoring systems are used to 
stratify patients with AF at risk for developing stroke and identify 
patients who may benefit from oral anticoagulation (OAC), including 
patients with AMI[8],[11],[12].Although antiplatelet drugs prevent 
thromboembolic complications in patients with AMI, particularly 
those receiving percutaneous interventions (PCI), these agents have 
minimal impact on stroke risk in patients with AF[11].
Therefore,prescription of OAC in addition to antiplatelet therapy 
is recommended for AMI patients with AF consistently in the ESC 
and ACC/AHA/HRS guidelines[11],[13].However, practice patterns 
vary widely, particularly when dual antiplatelet therapy is prescribed 
among AMI patients,largely due to concerns about the bleeding risk 
from “triple therapy”, but also because many providers view new-
onset AF following AMI as being associated with lower risk for 
stroke[14]. Observational studies have lent credibility to these concerns 
by showing an elevated bleeding risk among patients treated with 
dual antiplatelet agents and OAC[15].
Few investigations have described the epidemiology of AF among 
patients with AMI, further stratified according to stroke risk, or 
trends in OAC prescription and post-discharge complications among 
guideline-eligible AF patients with AMI. Therefore, we analyzed 
data from the multi-hospital, population-based, Worcester Heart 
Attack Study (WHAS)[7],[8],[16],[17].
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Abstract
Background: Atrial fibrillation (AF) is a common complication of acute myocardial infarction (AMI).The CHA₂DS₂VASc and CHADS₂risk 
scores are used to identify patients with AF at risk for stroke and to guide oral anticoagulants (OAC) use, including patients with AMI. However, 
the epidemiology of AF, further stratified according to patients’ risk of stroke, has not been well characterized among those hospitalized for 
AMI.
Methods: We examined trends in the frequency of AF, rates of discharge OAC use, and post-discharge outcomes among 6,627 residents 
of the Worcester, Massachusetts area who survived hospitalization for AMI at 11 medical centers between 1997 and 2011.
Results: A total of 1,050AMI patients had AF (16%) andthe majority (91%)had a CHA₂DS₂VASc score >2.AF rates were highest among 
patients in the highest stroke risk group.In comparison to patients without AF, patients with AMI and AF in the highest stroke risk category 
had higher rates of post-discharge complications, including higher 30-day re-hospitalization [27 % vs. 17 %], 30-day post-discharge death 
[10 % vs. 5%], and 1-year post-discharge death [46 % vs. 18 %] (p<0.001 for all). Notably, fewer than half of guideline-eligible AF patients 
received an OAC prescription at discharge. Usage rates for other evidence-based therapies such as statins and beta-blockers,lagged in 
comparison to AMI patients free from AF.
Conclusion: Our findings highlight the need to enhance efforts towards stroke prevention among AMI survivors with AF.
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Methods
The WHAS is an ongoing, population-based, observational 
study of patients hospitalized at all 11 medical centers in central 
Massachusetts, documenting long-term trends in the incidence, 
morbidity, mortality, and complications of AMI[7],[8],[1],[17]. Our 
analyses focused on patients who were hospitalized with a discharge 
diagnosis of AMI at all Worcester Standard Metropolitan Statistical 
Area (SMSA) hospitals during 8 biennial years between 1997 and 
2011. We selected these study years based on the availability of data 
on AF status, CHADS2 and CHA2DS2VASc scores, and systematic 
 Characteristics No AF 
[n=5577]
AF-
A2DS2VASc 
=1-2 [n=96]
AF- 
2VASc=3-
6 [n=798]
AF- 
2VASc=7-
9 [n=156]
p-value
Age (mean, years)[SD] 67.9 58.4 [8.6] 78.3 
[9.78]
81.8 [6.1] <. 001
Years[SD] [14.3]
Age <65 y (%) 39.2 68.7 8.1 1.3 <. 001
Age 65-74 21.3 16.6 21.5 8.3 <. 001
Age 75-84 24.1 0 37.8 53.2 <. 001
Age >= 85 y 15.3 14.6 32.4 37.2 <. 001
Sex, % Men 57.7 87.5 52.7 32.7 <. 001
White Race 89.4 89.6 92.5 94.2 0.01
AF Type
Incident 0 87.5 58.4 48.1 <. 001
Prevalent 0 12.5 41.6 51.9 <. 001
Medical History (%)
Angina Pectoris 16.2 10.4 16.8 21.1 0.15
Hypertension 69.1 26.1 77.9 96.1 <. 001
Heart Failure 20.9 5.2 29.8 64.1 <. 001
Stroke 10.6 0 7.0 64.1 <. 001
Diabetes 32.9 6.2 30.9 67.3 <. 001
Hyperlipidemia 54.9 44.8 51.2 56.4 0.06
COPD 15.9 17.7 22.7 19.2 <. 001
Prior bleeding 22.4 19.8 33.4 28.8 <. 001
CKD 16.2 13.5 22.9 35.9 <. 001
STEMI 36.6 57.3 28.8 27.5 <. 001
NSTEMI 63.4 42.7 71.2 72.5 <. 001
Initial AMI 65.0 82.3 62.4 58.3 <. 001
Creatinine in mg/dl 1.3 [1.0] 1.2 [0.7] 1.5[1.1] 1.6 [0.8] <. 001
- Mean [SD]
Troponin I Peak in 16.7 16.6 [49.6] 2 0 . 7 
[57.9]
2 4 . 9 
[75.6]
.029
ng/mL – Mean [SD] [65.5]
Mean HASBLED 1.6 [1.0] 0.7 [0.8] 2.0 [0.8] 3.0 [0.7] <. 001
score [SD]
Mean CHADS2VASc 3.8 [1.9] 1.6 [0.4] 4.5 [1.0] 7.4[0.6] <. 001
i n - H o s p i t a l 
C o m p l i c a t i o n s 
(%) 
Complicated AMI* 32.6 39.6 58.3 64.7 <. 001
Cardiogenic Shock 2.1 9.3 7.7 2.5 <. 001
Heart Failure 30.3 33.3 54.2 60.9 <. 001
Stroke 1.1 1.1 2.5 5.8 <. 001
Heart Block 1.2 6.3 3.1 2.5 <. 001
Recurrent AMI 0.7 0 0.5 0 0.5
Hospital Procedures 
(%)
Cardiac 59.2 71.9 43.7 30.8 <. 001
Catheterization
PCI 42.8 63.5 31.2 18.6 <. 001
* Complicated AMI included the development of cardiogenic shock, heart failure, stroke, recurrent 
AMI, or heart block.
Table 2:
Post-Discharge Outcomes* among Hospital Survivors of Acute 
Myocardial Infarction (AMI), further stratifiedaccording to Atrial 
Fibrillation (AF) Status
Outcome No 
AF
AF- CHA2DS2VASc  
1-2 
AF- CHA2DS2VASc 
3-6 
AF- CHA2DS2VASc    
7-9 
30 - day Re- 17.1 16.2 % 27.1 % 27 %
hospitalization** OR 0.9 (0.5-1.7) OR 1.5 (1.2-1.8) 1.2 (0.7-1.7)
30-day Mortality 4.9 7.3 %
OR 1.5 (0.7-3.4)
8.8 %
OR 1.3 (1-1.7)
10.3 %
OR 1.3 (0.7-2.3)
1- year Mortality 18 14.6 %
OR 0.8 (0.4-1.5)
33.9 %
OR 1.7 (1.4-2.1)
46.1 %
OR 2.2 (1.6-3.2)
collection of OAC prescription rates and post-discharge outcomes.
Since this study primarily focused on post-discharge outcomes and 
OAC prescription, patients who died during hospitalization were 
excluded. Medical records of patients admitted for possible AMI at all 
metropolitan Worcester medical centers were reviewed and validated. 
Diagnosis of AMI was confirmed using pre-established criteria[18]. 
The methods used for the identification of patients hospitalized 
Table 1:
 Demographic and Clinical Characteristics of Hospital Survivors of 
Acute Myocardial Infarction (AMI), further stratified according to 
Atrial Fibrillation (AF) Status
Figure 1:
Trends in the Rates of AFby CHA2DS2VASc Score between 1997 
and 2011
Figure 2:
Trends in the Rates of AF by CHADS2 Score between 1997 and 
2011.
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respiratory rate, serum creatinine and peak troponin), in-hospital 
and discharge medications, in-hospital complications and post-
discharge outcomes. Rates of warfarin, aspirin, and clopidogrel 
prescription were determined based on the discharge medication list. 
Rates of direct oral anticoagulant prescription were not examined 
in this study, as these agents were not approved for use in the US 
until 2010, nor collected in this study until after 2011. Rigorous 
methods have been used to identify deaths and cases of read mission 
to area hospitals[7]. Patient’s AF status was determined based on 
available clinical data[7],[16]. A review of ambulance transport records, 
emergency admission notes, progress notes, and in-hospital 12-lead 
ECGs was conducted to identify patients with AF. The classification 
of prevalent AF was assigned if a patient had prior AF noted in their 
hospital admission note or any progress note. A case of incident, or 
newly diagnosed, AF was defined according to the following criteria: 
No documentation of pre-existing AF anda) AF on any 12-lead ECG 
obtained during the index hospitalization[8],[17],  or b) new-onset AF 
documented in any clinical note during the index hospitalization. 
For purposes of focusing on post-discharge outcomes and discharge 
prescription practices, we included hospital survivors with both 
incident and prevalent AF. Patients who under went coronary artery 
bypass grafting (CABG) during hospitalizationwere excluded from 
the study due to the different mechanisms and natural historyof 
surgical patients with AF[19].
Patients with confirmed AMI were further stratified according to 
their CHA2DS2VAScscore based on documentation of risk factors 
in the medical record [age, sex, history of heart failure, hypertension, 
diabetes mellitus, stroke or transient ischemic attack, vascular disease 
(including myocardial infarction and peripheral artery disease)]
Medication No AF AF- 
CHA₂DS₂VASc 
1-2
AF- 
CHA₂DS₂VASc 
3-6
AF- 
CHA₂DS₂VASc 
7-9
p-value
Warfarin* 7.5 31.1 34.6 37.9 < .001
Dual Antiplatelet 
Therapy 
44.7 43.7 26.5 25 < .001
Aspirin only 86.4 88.5 80.7 78.2 < .001
Clopidogrel only 50.1 58.3 38.8 33.9 < .001
Beta Blockers 83.9 79.1 77.9 80.7 < .001
ACE/ARB 59.5 62.5 58 64.7 0.9
Lipid Lowering 
Agents
63.8 65.6 55.3 62.1 < .001
Triple Therapy * 4.4 19.7 15.2 10.3 < .001
* Data on Warfarin and Triple Therapy Rates collected from 2003-2011 only. n=3910.
CHADS₂≤1 CHADS₂≥2
Year
Warfarin
(%)
Aspirin Alone
(%)
Clopidogrel 
Alone 
(%)
DAPT (%) Triple 
Therapy  
(%)
Warfarin
(%)
Aspirin Alone
(%)
Clopidogrel 
Alone 
(%)
DAPT (%) Triple 
Therapy  
(%)
2003 35.3 29.4 5.9 51.0 17.7 32.5 40.8 3.2 36.3 7.6
2005 21.2 12.1 3.0 66.7 6.1 37.0 38.7 3.4 47.9 16.0
2007 30.6 38.9 2.8 50.0 16.7 38.8 38.8 0.0 50.5 14.6
2009 39.1 30.4 8.7 56.5 17.4 39.7 33.3 1.6 58.7 25.4
2011 36.4 30.3 0.0 60.6 24.2 32.8 27.7 3.1 54.7 15.6
Table 4:
Post-Discharge Prescription Rates of Warfarin, Antiplatelet Agents and Triple Therapy from 2003-2011 in Patients with Acute Myocardial 
Infarction (AMI) and Atrial Fibrillation (AF), further stratified by CHADS₂ Scores
* DAPT/Dual Antiplatelet Therapy = Aspirin + Clopidogrel
Medication AF Status 2003 2005 2007 2009 2011
Warfarin No AF 6.2 6.6 8.3 8 9.1
AF-CHA₂DS₂VASc 1-2 29.4 9.1 28.6 70 25
AF- CHA₂DS₂VASc 3-6 33.7 38.2 33 31.8 35.8
AF- CHA₂DS₂VASc 7-9 32.3 23.1 51.7 53.8 35.7
Triple Therapy No AF 2.3 4.4 5.5 5.5 4.9
AF- CHA₂DS₂VASc 1-2 17.6 0 28.6 40 18.8
AF- CHA₂DS₂VASc 3-6 10.9 16.5 12.6 20.6 22.4
AF- CHA2DS2VASc 7-9 2.9 7.7 20.7 23.1 0
Figure 3:
One-Year Mortality (Odds Ratio with 95 % Confidence Intervals) 
among AMI Patients with AF stratified by CHA₂DS₂VASc scores, 
compared to AMI Patients without AF.
Table 3:
Discharge Medication Prescription (%) among Hospital Survivors 
of Acute Myocardial Infarction with Atrial Fibrillation (AF), further 
stratified according to CHA2DS2VASc Score
with AMI and various comorbidities and complications have 
been described in prior publications[7],[8],[16],[17].  The data collected 
included patients’ age, gender, race, comorbidities (hypertension, 
heart failure, stroke, hyperlipidemia, chronic obstructive pulmonary 
disease [COPD], chronic kidney disease [CKD], diabetes), type of 
AMI,physiologic parameters (admission heart rate, blood pressure, 
Table 5:
Yearly Trends in Discharge Anticoagulation Prescription (%) in 
Patients with Acute Myocardial Infarction (AMI) and Atrial Fibrillation 
(AF), further stratified by CHA₂DS₂VASc scores
[11],[13]. Patients were grouped into 3 categories according to their 
CHA₂DS₂VASc score (Group 1 =CHA₂DS₂VASc score 1-2, 
Group 2 = CHA₂DS₂VASc 3-6, Group 3 = CHA₂DS₂VASc 7-9) 
to distinguish between those at lower, high, and very high risk of 
thromboembolism20-23. Although use of the CHA₂DS₂VASc stroke 
risk score was introduced in 2009, the CHADS₂ scoring system was 
in use for most of the period under study. Therefore, we also stratified 
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stroke risk category  were more likely to have new-onset AF compared 
to prevalent AF, whereas patients with AF in the highest stroke risk 
group were older, more likely to be male, have higher serum troponin 
levels, have a history of CKD, and have higher average HAS-BLED 
scores. Patients with AF and higher CHA2DS2VASc scores were 
also more likely to have their AMI hospitalization complicated by 
development of heart failure or stroke. We also observed that in 
patients with AMI and AF, bleeding risk (based on HAS-BLED 
score) tracked closely with stroke risk [Table 1].
Rates of AF increased significantly between 1997 and 2003, after 
which time AF rates remained relatively stable, and patterns did not 
appear to differ significantly according to CHA2DS2VASc stroke 
risk category[Figure 1]. Rates were highest among patients with 
AF in the highest stroke risk group, but the relative proportion of 
individuals in the lowest stroke risk category appeared to increase 
during the most recent study years. Similar results were seen in AF 
rates stratified by CHADS2 scores, with higher rates observed among 
patients with AF and a CHADS2 score≥2 [Figure 2].
 In comparison to AMI patients who remained free from AF 
during their hospitalization, individuals with AF in the highest 
stroke risk category had significantly higher rates of post-discharge 
complications, including higher 30-day re-hospitalization rates [27 
% vs. 17 %], 30-day  post-discharge death rates [10 % vs. 5%], and 
1-year post-discharge death rates [46 % vs. 18%] (p<0.001 for all). 
Notably, we observed a direct relationship between CHA2DS2VASc 
category and rates of readmission or death within 30 days, as well 
as death rates at 1-year [Table 2]. Furthermore, after adjustment 
for several demographic factors, comorbid conditions, and AMI-
associated characteristics, AF patients in the highest stroke risk group 
had 2-fold higher odds of dying at 1-year after discharge, compared 
to patients free from AF. However, adjustment for the same set of key 
covariates attenuated crude associations observed between stroke risk 
and readmission, as well as mortality 30-days after discharge [Table 
2].
 We also examined the use of evidence-based medications for AMI 
or AF at discharge, further stratified by stroke risk. Rates of OAC use 
were highest among patients with highest CHA2DS2VASc scores 
(38% in the very high stroke risk, 35% in the high stroke risk, and 
31% in the lowest stroke risk), but less than half of patients at high 
or very-high stroke risk received an OAC prescription at discharge. 
the cohort according to CHADS₂score (congestive heart failure, 
hypertension, age, diabetes, and stroke)using similar methods,but 
divided the population into two groups – those with CHADS₂  score 
less than two and those with a CHADS₂ score of two or more, in 
order to identify the proportion of the population eligible for OAC 
prescription based on contemporary guidelines[11],[13].    
We examined differences in the frequency and outcomes of patients 
with AF compared to those without AF through the use of chi-
square tests and one-way analysis of variance (ANOVA) for discrete 
and continuous variables, respectively. We examined differences in 
the characteristics and use of different evidence-based AMI and 
AF therapies according to stroke risk classifications through the 
Cochran-Armitage test for trends. Differences in post-discharge 
complications, including hospital re-admission and mortality, as 
well as the associated crude and multivariable adjusted odds ratios 
(OR) with 95% confidence intervals (CI), were assessed. The odds 
of developing these complications were adjusted for confounding 
demographic and clinical factors.
We restricted our analyses on post-discharge prescription rates 
of OAC to the study years 2003-2011 because data on OAC was 
not collected in this study until 2003. HAS-BLED scores were 
calculated to characterize participant’s risk of bleeding on OAC 
using the following factors documented in the medical record - 
age, hypertension, abnormal renal/liver function, stroke, bleeding 
history, drugs or alcohol use (1 pointeach)[11],[21]. Since INRs prior to 
admission were not abstracted as part of this population-based study, 
we were not able to determine time in therapeutic range over
the preceding 4 weeks among individuals treated with vitamin K 
antagonists. Hospital re-admission data was collected at only 3 of the 
major Worcester hospitals, and was reported for the years 1999-2011. 
All analyses were performed using SAS version 9.3 (SAS Institute 
Inc., Cary, NC).
Results
The baseline characteristics of 6,627 patients discharged from 
all participating medical centers in central Massachusetts with an 
independently confirmed AMI during the years under study are 
shown in [Table 1]. The mean age of this population sample was 
69 years, 40% were women, and approximately two-thirds presented 
with an initial AMI. A total of 1,050patients (16%) had AF. Of these, 
the majority were at a high (76 %) or very high risk (15 %) for stroke 
according to their CHA2DS2VASc score. Patients in the “lower” 
Medication Overall
N=1050
Low                                          High
HASBL                                     HASBL
ED                                           ED
AF-CHADS₂VASc   1-2
N=96
Low                                          High
HASBL                                    HASBL
ED                                             D
AF-CHADS₂VASc   >2
N=954
Low                                                   High
HASBL                                              HASBL
ED                                                     D
p- value 
Warfarin* 36.4                                          32 31.6                                            25 37.1                                                        32.1 0.2
DAPT 28.7                                          25.9 43.4                                            50 26.6                                                       25.6 0.3
Aspirin only 82.2                                          78.2 89.1                                            75 81.2                                                       78.2 0.1
Clopidogrel only 41.3                                         36.5 58.7                                            50 38.8                                                        36.3 0.1
Triple Therapy * 17.5                                           9.7 21                                                 0 17                                                             9.8             0.005
*  DAPT/Dual Antiplatelet Therapy = Aspirin + Clopidogrel
Table 6: Discharge Medication Prescription (%) among Hospital Survivors of Acute Myocardial Infarction (AMI) with Atrial Fibrillation (AF), further stratified according to Risk of Bleeding 
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AMI and AF had a high or very high risk for thromboembolism 
based on having a CHA₂DS₂VASc score>2. However, only 1 out of 4 
AMI patients with AF received dual antiplatelet therapy at the time 
of hospital discharge and less than half received OAC at discharge, 
suggesting thata treatment gap between guideline and real-world 
rates of prescription exists.
Reasons for the low rates of  OAC usage among AMI patients with 
AF at hospital discharge may include lack of awareness of guidelines, 
provider or patient concerns over risk for bleeding with the use of 
OAC and antiplatelet drugs, or under-estimation of stroke risk from 
AF complicating AMI. Since the FDA approved the first target 
specific OAC agent, dabigatran, for use in 2010 and our study ended 
in 2011, we do not believe that the low rates of OAC seen in our study 
relate to the use of vitamin-K antagonist alternatives. Furthermore, 
we have generally observed high rates of adherence to AMI-specific 
guideline recommendations for effective patient management in 
this community-wide study, with the majority of eligible patients 
having been treated with aspirin, statins, beta-blockers and prompt 
percutaneous revascularization for STEMI[31]. This was corroborated 
in our analysis as the vast majority of AMI patients with AF received 
guideline-directed antiplatelet, lipid-lowering agents, and beta-
blocker therapies [Table 3]. Therefore, we do not believe that the low 
rate of observed OAC prescription reflects a general disregard among 
providers at participating hospitals for guideline recommendations. 
An alternative explanation for our findings is that, despite evidence to 
the contrary(7), hospital providers may consider AF complicating an 
AMIto be of lesser clinical significance than AF in the community, 
irrespective of their CHADS₂ or CHA₂DS₂VASc scores.
Neither treatment   nor outcomes of A Fare mandated publically 
reported quality metrics.It has not been until recently that the 
American Heart Association created and distributed a ‘Get with the 
Guidelines’ for AF, a mechanism to enhance adherence to guideline-
recommendations for AF treatment, including use of OAC for 
patients at intermediate and high stroke risk[32]. It is certainly 
possible that clinicians managing patients with AMI during the 
period under study may not have been aware of the importance of 
stroke risk estimation and OAC prescription for at-risk patients. It is 
our hope that, through increased public and clinician AF awareness, 
adherence to guideline recommendations for OAC among eligible 
AMI patients with AF will increase.
Strengths of the present study include the population-based 
design involving all patients hospitalized with AMI across central 
Massachusetts. Inclusion of all regional hospitals in Worcester, the 
large number of patients hospitalized with AMI and AF, and the use 
of standardized criteria for diagnosing AMI and AF were additional 
strengths. We were also able to control for a variety of potential 
confounding variables outside of the CHA₂DS₂VASc scoring system 
that could have contributed to post-discharge outcomes.
Limitations
Limitations of this study include the lack of data on type of AF 
(paroxysmal, persistent, or permanent) and the inability to determine 
the time in therapeutic INR range among patients with AF prior 
to admission. Our study population likely included a number of 
patients at high risk for bleeding, and we did not systematically assess 
Interestingly, aspirin and clopidogrel use were also lower among AMI 
patients with AF at highest stroke risk,compared to those at lower 
risk (88.5 % and 58.3% among those with AF in the lowest stroke 
risk category vs. 78.2 % and 33.9% among those with AF highest 
stroke risk, respectively). In contrast, prescription of beta-blockers 
and lipid-lowering agents did not vary among AF patients based on 
stroke risk [Table 3].  
Notably, only 1 in 4 AMI patients with AF and a high or very 
high stroke risk score received dual antiplatelet therapy at hospital 
discharge. Low rates of OAC prescription at discharge were also 
observed when stratifying the patients based on their CHADS2 
score[Table 4]. We did not observe any significant change in the 
rates of OAC prescription over time among individuals with AF 
[Table 5]. Lastly, in AF patients at elevated stroke risk, we observed 
no significant relations between bleeding risk and rates of OAC 
prescription at discharge [Table 6].
Discussion
The CHA₂DS₂VASc scoring system is a well-validated stroke 
risk stratification tool  for  patients with non-valvular AF[24]. 
Components of the CHA₂DS₂VASc score are readily available 
prognostic risk factors for outcomes of is chemic heart disease[25].
The CHA₂DS₂VASc score has been shown to successfully estimate 
the risk of adverse events in patients with AMI[24] and also identify 
post-STEMI patients at high risk of developing new onset AF and 
stroke[26].
There are limited studies that have evaluated the prognostic utility 
of stroke risk classification schemes in predicting the risk of adverse 
outcomes in patients with concomitant AMI and AF.In a study of 
more than 15,000 patients admitted with AMI to hospitals in Korea, 
the investigators assessed the utility of CHA₂DS₂VASc scores in 
predicting the risk of dying and/or recurrent MI in patients with and 
without AF.  They found that higher CHA₂DS₂VASc scores were 
associated with an increased risk of adverse cardiovascular outcomes in 
AMI patients at 1,6,12, and 24 months, irrespective of the presence of 
AF[27]. In our community-wide study involving almost 7,000 hospital 
survivors, patients with AF and a higher CHA₂DS₂VASc scores were 
at greater risk for both short- and long- term adverse events than 
both AF patients with lower CHA₂DS₂VASc scores, and patients 
without AF. In particular, we observed a direct relationship between 
increasing CHA₂DS₂VASc scores and odds of dying at 1-year after 
discharge in patients with AF, compared to patients free from AF. 
This was not seen in AF patients with a low CHA₂DS₂VASc score 
[Figure 3]. Our findings expand on the results of the previous Korean 
study (27), and suggest that the CHA₂DS₂VASc system can be used 
as a tool to predict survival among patients with AMI and AF.
Current AF and AMI management guidelines support the use of 
dual antiplatelet therapy plus OAC when independent indications 
for AMI and AF exist[28],[29]. However, institution of “triple therapy” 
poses risks for bleeding. Inasmuch, alternative strategies have been 
proposed for patients with AMI and AF, such as discontinuing 
antiplatelet drugs among patients who are greater than 12 months 
out from undergoing a PCI[30]. In clinical practice, there is significant 
individualization of treatment with respect to balancing the risks of 
stroke and bleeding.In our study, approximately 90% of patients with 
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23. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman 
JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, 
components of frailty,  such as falls, weight loss, or grip strength, which 
may influence decisions to with hold OAC. We also did not assess for 
patient-level factors, such as patient’s attitudes about OAC, allergies 
or prior adverse reactions that may have led to the with holding of 
OAC’s at the time of hospital discharge.Data on prescription rates of 
anti arrhythmic medications in patients with AF was not collected. 
Since this study was conducted in a single geographic region, there was 
potential for under-estimation of re-hospitalization rates, as patients 
may have presented outside of the hospital network for subsequent 
hospitalizations. Moreover, hospital re-admission data was reported 
at only 3 of the major Worcester hospitals, although these comprise 
the majority of all AMI admissions in this population. Data on the 
etiology of death after hospital discharge was not available.
Conclusions
We observed that a large proportion of patients hospitalized for 
AMI over a 14-year period had AF,and that the proportion of AF 
patients at high risk for stroke remained elevated throughout the 
study. Another interesting finding was that less than half the patients 
with a high CHA2DS2VASc were discharged on anticoagulation 
therapy. Our findings suggest significant deviation from guideline-
based AF management practices in the context of AMI, and that 
patients with higher CHA2DS2VASc scores may benefit from greater 
monitoring and/or more aggressive treatment in the peri-discharge 
period. Future studies are needed to see if the CHA2DS2VASc score 
can truly be validated as tool for not only predicting stroke risk, but 
also post-discharge outcomes (including mortality) in patients with 
AMI and AF.
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